Biotech IPO activity accelerated this week with several drug developers tapping public markets. Eikon Therapeutics priced an upsized offering that raised approximately $381 million to advance its clinical candidates, while Agomab Therapeutics and SpyGlass Pharma completed offerings that together added hundreds of millions in new capital for immunology and ocular pipelines. The transactions underscore renewed investor appetite for clinical‑stage biotech after a prolonged lull. Proceeds are earmarked for Phase II/III trials and platform scaling; several companies signaled plans to prioritize advancement of lead assets. For industry executives and investors, the listings suggest improved market receptivity to differentiated pipelines and capital for late‑stage development.